Abstract
The farnesoid X receptor (FXR) is a bile acid-activated nuclear receptor which is abundant in the liver, intestine, and kidney. FXR is a pivotal factor in cholesterol/bile acid homeostasis but is involved in the growth of hepatocellular carcinoma cells. In the present study, we investigated whether FXR is also involved in the growth of renal adenocarcinoma cells. The cell growth of renal adenocarcinoma cell line ACHN was inhibited by FXR knockdown and stimulated by FXR ligand, while that of a normal renal cell-derived cell line, HK-2, was not affected. The carcinoma-specific stimulation of cell growth by FXR was found to arise from down-regulation of p53 and p21/Cip1 mRNA expression. Our study showed that FXR stimulates proliferation of renal adenocarcinoma cells and that FXR knockdown is useful for growth suppression of renal adenocarcinoma without cytotoxicity to normal renal cells.
References
Jun 2, 1995·Cell·B M FormanC Weinberger
Jan 1, 1994·Kidney International·M J RyanB Torok-Storb
Nov 19, 1993·Cell·W S el-DeiryB Vogelstein
May 21, 1999·Science·M MakishimaB Shan
May 21, 1999·Science·D J ParksJ M Lehmann
Jun 9, 1999·Molecular Cell·H WangB M Forman
Jun 14, 2002·Gene·Reid M HuberTimothy C Burn
Jan 20, 2004·Genes & Development·Yanqiao ZhangPeter A Edwards
Sep 3, 2004·Journal of Lipid Research·Audrey SirventBart Staels
Nov 21, 2007·FEBS Letters·Yanqiao Zhang, Peter A Edwards
Mar 27, 2012·Molecular Cancer Research : MCR·Yan ZhangFengtian He
Sep 13, 2012·Journal of Biochemistry·Tomofumi FujinoMakio Hayakawa
Jan 3, 2013·Cancer·Baoxiang GuanXiaochun Xu
Oct 28, 2014·Bioscience, Biotechnology, and Biochemistry·Tomofumi FujinoMakio Hayakawa
Jul 15, 2015·The Journal of Toxicological Sciences·Tomofumi FujinoMakio Hayakawa
Aug 19, 2015·Gut·Heng WuGuisheng Song
Aug 26, 2015·Molecular Cancer·Jialin HeFengtian He
Sep 30, 2015·Oncotarget·Fei GuoFengtian He
Jan 6, 2016·Scientific Reports·Yang XieHaiping Hao
Citations
Dec 24, 2018·Expert Opinion on Therapeutic Targets·Christos Masaoutis, Stamatios Theocharis
Feb 1, 2018·Oncotarget·John P PhelanFergal O'Gara
Jul 12, 2020·BMC Cancer·L AbsilD Nonclercq
Jan 15, 2020·The Journal of Toxicological Sciences·Tomofumi FujinoMakio Hayakawa
Oct 6, 2020·Frontiers in Oncology·Xiaoyan LiuWei Sun
Dec 15, 2020·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Kyounghwa JungDonghun Shin